Dapagliflozin is a Oral Tablet in the Human Prescription Drug category. It is labeled and distributed by Lupin Pharmaceuticals, Inc.. The primary component is Dapagliflozin.
Product ID | 70748-105_b2ba541f-f831-499b-9161-c54ae831900c |
NDC | 70748-105 |
Product Type | Human Prescription Drug |
Proprietary Name | Dapagliflozin |
Generic Name | Dapagliflozin |
Dosage Form | Tablet |
Route of Administration | ORAL |
Marketing Start Date | 2018-11-15 |
Marketing Category | ANDA / ANDA |
Application Number | ANDA211531 |
Labeler Name | Lupin Pharmaceuticals, Inc. |
Substance Name | DAPAGLIFLOZIN |
Active Ingredient Strength | 5 mg/1 |
Pharm Classes | Sodium-Glucose Cotransporter 2 Inhibitor [EPC],Sodium-Glucose Transporter 2 Inhibitors [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2019-12-31 |
Marketing Start Date | 2018-11-15 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | ANDA |
Application Number | ANDA211531 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-11-15 |
Inactivation Date | 2020-01-31 |
Marketing Category | ANDA |
Application Number | ANDA211531 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-11-15 |
Inactivation Date | 2020-01-31 |
Marketing Category | ANDA |
Application Number | ANDA211531 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-11-15 |
Inactivation Date | 2020-01-31 |
Marketing Category | ANDA |
Application Number | ANDA211531 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2018-11-15 |
Inactivation Date | 2020-01-31 |
Ingredient | Strength |
---|---|
DAPAGLIFLOZIN | 5 mg/1 |
NDC | Brand Name | Generic Name |
---|---|---|
70748-106 | Dapagliflozin | Dapagliflozin |
70748-105 | Dapagliflozin | Dapagliflozin |
0310-6205 | FARXIGA | DAPAGLIFLOZIN |
0310-6210 | FARXIGA | DAPAGLIFLOZIN |
50090-3481 | FARXIGA | DAPAGLIFLOZIN |
50090-3482 | FARXIGA | DAPAGLIFLOZIN |
55154-6932 | FARXIGA | DAPAGLIFLOZIN |